Cayston® is the first CF drug to advance - from beginning to end - through the Cystic Fibrosis Foundation's Therapeutics Development Program.
Cayston, formerly known as AZLI, is for the treatment of Pseudomonas aeruginosa. It was approved by the U.S. Food and Drug Administration last week.
If you are interested in Cayston, talk to your CF doctor.
Cayston is administered with a new device called the Altera® Nebulizer System that allows patients to take the medicine in less than five minutes, a fraction of the time required for other inhaled antibiotics. It is the first new inhaled antibiotic developed for CF in more than a decade.
To support CF patients, Gilead Sciences, Inc., maker of Cayston, is launching a Cayston Access Program, a call center established with a nonprofit subsidiary of the Cystic Fibrosis Foundation.
The program helps people with CF and members of their care team with insurance verification, co-pay assistance and claims support. For information, visit www.Cayston.com or call 1-877-7CAYSTON (877-722-9786).
For most patients with private insurance, the prescription cost will be limited to a co-pay of $25, as a result of Gilead's support.
If you do not have insurance, Gilead has a special program that offers Cayston free to individuals with CF who meet the eligibility criteria. To learn more, call the Cayston Access Program.
The CF Foundation played an important role in the development of Cayston.
- View the official Cayston Web site